Venus Remedies Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Venus Remedies has postponed the meeting of the Board of Directors which was scheduled to be held on 20 July 2024. The meeting will now be held on a later date.

Powered by Capital Market - Live News

Venus Remedies will hold a meeting of the Board of Directors of the Company on 20 July 2024.

Powered by Capital Market - Live News

Pan American Health Organisation (PAHO) is the world’s oldest international public health agency.

The Chandigarh-based company will be supplying a wide range of essential oncology drugs like bleomycin, carboplatin, cisplatin, cytarabine, doxorubicin, irinotecan, methotrexate, and vincristin.

This achievement signifies a major milestone for Venus Remedies, enhancing its contribution to global health initiatives and reinforcing its commitment to improving global health outcomes,” Venus Remedies said in a statement.

Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation.

The company’s consolidated net profit declined 4.97% to Rs 10.51 crore in Q4 FY24 from Rs 11.06 crore posted in Q4 FY23. Revenue for Q4 FY24 stood at Rs 195.16 crore in Q4 FY24, up 25.39% YoY.

Powered by Capital Market - Live News

The company had earlier received GMP (Good Manufacturing Practices) approval from UNICEF.

Our Ceftriaxone 1gm product has met and surpassed stringent quality criteria, demonstrating our dedication to producing top-tier pharmaceutical solutions. This award not only highlights our product's superior quality but also reinforces our role as a trusted partner in global health initiatives,” Venus Remedies said in a statement.

Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation.

The company’s consolidated net profit declined 4.97% to Rs 10.51 crore in Q4 FY24 from Rs 11.06 crore posted in Q4 FY23. Revenue for Q4 FY24 stood at Rs 195.16 crore in Q4 FY24, up 25.39% YoY.

Powered by Capital Market - Live News